Physician profile
Brian Naizer
NPI 1528551991
$946.91
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $43.56 · 2022: $330 · 2023: $338 · 2024: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $573.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $161.39 | 2022-2024 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $139.61 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.38 | 2022-2024 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Abbvie INC. | $76.97 | 2022-2024 | |
| Exact Sciences Corporation | $64.59 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $57.13 | 2022-2023 | Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $43.99 | 2023-2024 | Arexvy, Shingrix |
| Corcept Therapeutics | $43.56 | 2021 | |
| Pfizer INC. | $34.05 | 2022 | |
| Neurocrine Biosciences, INC. | $30.61 | 2023-2024 | Ingrezza |
| Astrazeneca Pharmaceuticals Lp | $28.78 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.10 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $23.92 | 2024 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $22.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.36 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $17.45 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.73 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Naizer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.